SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA
Q3 Medicine
D. Dytfeld, J. Radocha, R. Hájek, Guldane Cengiz-Seval, Meral Berkac, D. Coriu, B. Derman, A. Jakubowiak, V. Pečeliūnas, Gabor Mikkala, Ł. Bołkun, D. Hawrylecka, S. Grosicki, A. Tyczyńska, J. Zaucha, Wanda Knopińska, G. Semeńczuk, M. Morawska, K. Giannopoulos, A. Puła, M. Rymko, G. Charliński, A. Szeremet, E. Kalicińska, Lidia Usnarska, T. Wróbel, K. Jamroziak, A. Druzd-Sitek, Joanna Romejko Jarosińska, W. Sawicki, A. Waszczuk-Gajda, A. Juda, M. Hus, L. Gil
求助PDF
{"title":"SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA","authors":"D. Dytfeld, J. Radocha, R. Hájek, Guldane Cengiz-Seval, Meral Berkac, D. Coriu, B. Derman, A. Jakubowiak, V. Pečeliūnas, Gabor Mikkala, Ł. Bołkun, D. Hawrylecka, S. Grosicki, A. Tyczyńska, J. Zaucha, Wanda Knopińska, G. Semeńczuk, M. Morawska, K. Giannopoulos, A. Puła, M. Rymko, G. Charliński, A. Szeremet, E. Kalicińska, Lidia Usnarska, T. Wróbel, K. Jamroziak, A. Druzd-Sitek, Joanna Romejko Jarosińska, W. Sawicki, A. Waszczuk-Gajda, A. Juda, M. Hus, L. Gil","doi":"10.5603/ahp.a2023.0016","DOIUrl":null,"url":null,"abstract":"Introduction: Despite several studies, the impact of coronavirus disease 2019 on patients with multiple myeloma remains uncertain. Material(s) and Method(s): We performed a survey that covered the period of the first and second waves of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in 23 centers inseven countries. Out of 352 patients with myeloma and SARS-CoV-2, 23% died. Results/Conclusions: Logistic regression showed a lower risk of death among patients treated with proteasome inhibitor and a higher risk of death for those who had a severe or a very severe course of disease.Copyright © 2023 Sciendo. All rights reserved.","PeriodicalId":35805,"journal":{"name":"Acta Haematologica Polonica","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Haematologica Polonica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/ahp.a2023.0016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
引用
批量引用
Abstract
Introduction: Despite several studies, the impact of coronavirus disease 2019 on patients with multiple myeloma remains uncertain. Material(s) and Method(s): We performed a survey that covered the period of the first and second waves of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in 23 centers inseven countries. Out of 352 patients with myeloma and SARS-CoV-2, 23% died. Results/Conclusions: Logistic regression showed a lower risk of death among patients treated with proteasome inhibitor and a higher risk of death for those who had a severe or a very severe course of disease.Copyright © 2023 Sciendo. All rights reserved.
多发性骨髓瘤患者的SARS-CoV-2感染:在欧洲和美国23个中心的调查
引言：尽管进行了几项研究，但2019冠状病毒病对多发性骨髓瘤患者的影响仍不确定。材料和方法：我们在23个国家的中心进行了一项调查，涵盖了严重急性呼吸综合征冠状病毒2型（严重急性呼吸系统综合征冠状病毒冠状病毒2型）疫情的第一波和第二波。352名骨髓瘤和严重急性呼吸系统综合征冠状病毒2型患者中，23%死亡。结果/结论：Logistic回归显示，接受蛋白酶体抑制剂治疗的患者的死亡风险较低，而有严重或非常严重病程的患者的死亡率较高。版权所有©2023 Sciendo。保留所有权利。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
